SCHEMBL29501787

SCHEMBL29501787

COc1ccnc(C(=O)N[C@@H](C)C(=O)OC2CCC2c2ccc(Cl)cc2Cl)c1O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.34
TP53 P04637 3/20 0.34
KDM4C Q9H3R0 1/20 0.34
STAT3 P40763 1/20 0.33
CNR2 P34972 1/20 0.33
ALDH1A1 P00352 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
FLT1 P17948 1/20 0.32
FLT4 P35916 1/20 0.32
KDR P35968 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 2/20 0.32
CNR1 P21554 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
DPP4 P27487 1/20 0.32
EPHX2 P34913 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23680937 1.00 LMNA (0.34) LMNATP53KDM4CSTAT3CNR2
SCHEMBL29501757 0.88 IDO1 (0.35) LMNATP53HTTRAB9A
SCHEMBL23680918 0.88 IDO1 (0.35) LMNATP53HTTRAB9A
SCHEMBL23680966 0.84 HCRTR1 (0.34) KDRANO1
SCHEMBL29501802 0.84 HCRTR1 (0.34) KDRANO1
SCHEMBL23680931 0.80 NR3C2 (0.34) FLT1FLT4KDRANO1
SCHEMBL29501811 0.80 NR3C2 (0.34) FLT1FLT4KDRANO1
SCHEMBL29501780 0.76 TP53 (0.34) LMNATP53KDM4CSMN1; SMN2HTT
SCHEMBL23680928 0.76 TP53 (0.34) LMNATP53KDM4CSMN1; SMN2HTT
SCHEMBL17905461 0.75 SMN1; SMN2 (0.36) LMNATP53ALDH1A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710429-B1 MICROBIOCIDAL PICOLINAMIDE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2023-04-05 EP disclosed
US-11291205-B2 Microbiocidal picolinamide derivatives SYNGENTA PARTICIPATIONS AG (CH) 2022-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11291205-B2 Microbiocidal picolinamide derivatives CASP2, CASP1, MSR1 LMNA 3958/4885TP53 3878/4885KDM4C 4224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.